semaglutide 503b Personalized Compounded HIMS to Introduce Compounded GLP-1

Exp Ther Med 15:50775083 Mieczkowska A, Millar P, Chappard D, Gault VA, Mabilleau G (2020) Dapagliflozin and liraglutide therapies rapidly enhanced bone material properties and matrix biomechanics at bone formation site in a type 2 diabetic mouse model

When a source says one is stronger than the other, it is lining up REDEFINE 1s roughly 20.4% at 68 weeks against SURMOUNT-1s roughly 20.9% at 72 weeks two numbers from two different trials, in different populations, over different durations, against different comparators

For patients who want to understand what good clinical oversight of GLP-1 treatment looks like in practice, including what lab work and monitoring to expect, the article on what lab tests to expect while on GLP-1 medications provides a useful reference

It was placed on the FDAs 503A Category 2 bulk-substances list in September 2023, a designation that restricted its use in pharmacy compounding